| Title | The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder. | | Author(s) | Jessen L, Kovalick LJ, Azzaro AJ | | Source | P T 2008 Apr; 33(4):212-46. | | Abstract | Although monoamine oxidase inhibitors (MAOIs) at one time represented the mainstay of therapy for major depressive disorder (MDD), the risk of acute hypertensive reactions following the ingestion of tyramine-rich foods and the consequent need to restrict dietary tyramine represent a barrier to their use. In this article, we present an overview of the efficacy and safety of a transdermal formulation of the MAOI selegiline for the treatment of MDD. Transdermal delivery of selegiline at the effective dose of 6 mg every 24 hours eliminates the need for a tyramine-restricted diet. Our emphasis on potential drug-drug interactions and contraindications should be useful to prescribers who counsel patients with MDD. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19750165 |
|
